Market news

Addition of three sites strengthens expectation to complete enrollment by year-end 2026BURLINGTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced that six hospital sites in Australia are now under agreement to participate in its first-in-human pilot clinical trial of NB1, the Company’s rhNELL-1-based bone graft product for spinal fusion. Th

BURLINGTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel. Jeff Frelick, Chief Executive Officer of Bone Biologics will hold one-on-one meetings with investors

Bone Biologics has extended the validated shelf life of its rhNELL-1 protein to 32 months, giving the company greater manufacturing and supply-chain flexibility as it prepares for larger-scale clinical development and advances enrollment in its first-in-human NB1 study. Key Investor TakeawaysBone Biologics (NASDAQ:BBLG) has achieved a 32-month validated shelf life for rhNELL-1, extending the 29-month milestone reported in May 2026.

Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 million. Definium Therapeutics

Milestone strengthens manufacturing flexibility and supports pivotal study readinessBURLINGTON, Mass, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announces that the validated shelf life of its rhNELL-1 protein has been extended to 32 months. “Reaching a 32-month validated shelf life gives us greater flexibility in how we manufacture, store and distribu

Strengthened capital position supports continued advancement of NB1 clinical development, manufacturing readiness and intellectual property initiatives through Q2 2027BURLINGTON, Mass, July 23, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets, today issued a shareholder update summarizing the Company’s progress through the first half of 2026, including its recently complet

By Brad Sorensen, CFA NASDAQ: BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics' (NASDAQ: BBLG) latest financing announcement is an important step toward advancing the company's clinical development strategy by strengthening its balance sheet and providing additional capital to support execution. While financing transactions often create concerns about dilution, this placement is designed to